The groundbreaking treatment of the medication represents a major development in the handling of type 2 diabetes. Different to existing therapies, tirzepatide targets dual pathways – glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) – leading to enhanced blood